Wen Shen, MD, describes perimenopause as an opportunity for clinicians to revisit pregnancy-related risk factors and address cardiovascular health proactively.
|Podcasts|August 5, 2021
Pap Talk S3 E11: Meet the Board: Christine Isaacs, MD
Author(s)Lindsey Carr, Editor, Christine Isaacs, MD
Introducing Contemporary OB/GYN® Editorial Advisory Board member, Christine Isaacs, MD.
Advertisement
Christine Isaacs, MD is one of Contemporary OB/GYN®’s newest
Advertisement
Related to this article
A recap of the top videos and podcasts from Contemporary OB/GYN in September 2026, featuring expert interviews on salpingectomy, testosterone evidence, and more.
A new study finds that low birth volume and unprofitability were strongly associated with both obstetric unit and full hospital closures between 2010 and 2023.
A recap of the top headlines from Contemporary OB/GYN in September 2026, spanning ACOG's respiratory vaccine guidance to the launch of the Missed & Dismissed podcast.
A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.
Fezolinetant was linked to VMS and sleep improvements by week 4 in the real-world OPTION-VMS study, presented at the International Menopause Society World Congress.
Wen Shen, MD, highlights perimenopause as an important period for identifying health risks and supporting healthy aging beyond the menopausal transition.
A global consensus published in The Lancet has officially renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome, a change with broad implications for diagnosis, care, and cardiometabolic screening.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
IMS: Fezolinetant's improvements in sleep quality, hot flashes as early as week 4
2
Top headlines in women's health from September 2026
3
Wen Shen, MD, on recognizing perimenopause as a window for healthy aging
4
FDA grants priority review to elinzanetant for VMS in women receiving endocrine therapy for breast cancer
5